Anne Schoenle

8PUBLICATIONS
77CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical devicesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 28, 2022
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.

Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto

|Aug 02, 2022
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.

Raffaella Iurlaro, Inja Waldhauer, Ester Planas-Rigol

|Jul 28, 2022
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.

Sophia Stock, Mohamed-Reda Benmebarek, Anna-Kristina Kluever

|Mar 27, 2021
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.

Eva Sum, Moritz Rapp, Philipp Fröbel

|Jun 26, 2020
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.

Martina Geiger, Kay-Gunnar Stubenrauch, Johannes Sam

|Jun 14, 2019
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Christina Claus, Claudia Ferrara, Wei Xu

Pageof 2

Frequent Collaborators

7 joint publications

Christiane Neumann

3 joint publications

Pablo Umaña

3 joint publications

Johannes Sam

2 joint publications

Sebastian Kobold